RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q3 2022
Top Holdings81 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 7.6M | $781.5M | 16.7% | $95.96 | +6.94% | 16 qtrssince 2018-Q4 | Unchanged 0 |
BIOGEN IDEC INC | 937,549 | $250.3M | 5.3% | $222.99 | +18.52% | 3 qtrssince 2022-Q1 | Increased 75 |
CYTEK BIOSCIENCES INC | 13.4M | $197M | 4.2% | $18.15 | -21.70% | 5 qtrssince 2021-Q3 | Unchanged 0 |
FORMA THERAPEUTICS HLDGS INC | 9M | $179.8M | 3.8% | — | — | 10 qtrssince 2020-Q2 | Unchanged 0 |
DAY ONE BIOPHARMACEUTICALS I | 7M | $141M | 3.0% | $19.64 | -0.08% | 6 qtrssince 2021-Q2 | Unchanged 0 |
| 8.3M | $137M | 2.9% | — | — | 6 qtrssince 2021-Q2 | Unchanged 0 | |
RHYTHM PHARMACEUTICALS INC | 5.5M | $134M | 2.9% | $23.43 | +1.89% | 16 qtrssince 2018-Q4 | Increased 58 |
TRAVERE THERAPEUTICS INC | 4.9M | $121.3M | 2.6% | $26.96 | -8.60% | 8 qtrssince 2020-Q4 | Unchanged 0 |
BELLUS HEALTH INC NEW | 11.4M | $120.2M | 2.6% | — | — | 4 qtrssince 2021-Q4 | Increased 57 |
JANUX THERAPEUTICS INC | 8.7M | $117.4M | 2.5% | $25.37 | -47.30% | 6 qtrssince 2021-Q2 | Unchanged 0 |
VAXCYTE INC | 4.6M | $109.9M | 2.3% | $29.78 | -16.81% | 10 qtrssince 2020-Q2 | Unchanged 0 |
DICE THERAPEUTICS INC | 5.2M | $105.6M | 2.3% | — | — | 5 qtrssince 2021-Q3 | Unchanged 0 |
IMMUNOGEN INC | 21.7M | $103.9M | 2.2% | — | — | 9 qtrssince 2020-Q3 | Unchanged 0 |
NKARTA INC | 7.8M | $102.7M | 2.2% | $25.19 | -49.86% | 9 qtrssince 2020-Q3 | Unchanged 0 |
ACUMEN PHARMACEUTICALS INC | 9.8M | $98M | 2.1% | $14.85 | -29.43% | 5 qtrssince 2021-Q3 | Unchanged 0 |
Legend Biotech Corp. Sponsored ADR | 2.3M | $95.4M | 2.0% | $40.11 | 0.00% | 1 qtr | New 77 |
ITEOS THERAPEUTICS INC | 4.4M | $84.1M | 1.8% | — | — | 9 qtrssince 2020-Q3 | Unchanged 0 |
RELMADA THERAPEUTICS INC | 2M | $74M | 1.6% | $21.71 | +66.70% | 4 qtrssince 2021-Q4 | Unchanged 0 |
PEPGEN INC | 8.1M | $73.8M | 1.6% | $10.40 | -19.62% | 2 qtrssince 2022-Q2 | Unchanged 0 |
GERON CORP | 30.1M | $70.5M | 1.5% | $2.10 | +10.00% | 10 qtrssince 2020-Q2 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $4.7B across 81 positions as of Q3 2022. Top holdings: ASND (16.7%), BIIB (5.3%), CTKB (4.2%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 13 new positions, 20 exits, 10 increased. Top move: LEGN (NEW, conviction 77). Portfolio: $4.7B across 81 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer